• Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • Home
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu

Captare. Aestimare. Eligere. Succedere.

CAPTIS – Your Global Healthcare & MedTech Executive Search Provider

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

GET HEADHUNTED!

Create and/or update

your confidential profile

 

Healthcare Executive General Information
Create an account & Add your profile

Go to our Careers page

 

 

 

 

 

CAPTIS Careers

Recent Healthcare News:

05/24/2019/by CAPTIS

Nektar Therapeutics launches Inheris Biopharma

Inheris will be responsible for launch preparation and commercialization…
05/24/2019/by CAPTIS

UCSF doses first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA

05/23/2019/by CAPTIS

Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials

05/23/2019/by CAPTIS

GSK gets Chinese approval for shingles vaccine Shingrix

05/23/2019/by CAPTIS

Cyclica launches new multi-targeted drug design technology Ligand Design

05/23/2019/by CAPTIS

FDA approves SORILUX for adolescent plaque psoriasis

05/23/2019/by CAPTIS

Amgen to acquire Danish firm Nuevolution for £132m

05/22/2019/by CAPTIS

Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease

05/22/2019/by CAPTIS

WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract

05/21/2019/by CAPTIS

Merck to buy Peloton Therapeutics in £1.72bn deal

05/21/2019/by CAPTIS

SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors

Desmoid tumors are rare and often debilitating and disfiguring…
05/21/2019/by CAPTIS

AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma

05/20/2019/by CAPTIS

Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon

05/20/2019/by CAPTIS

US FDA approves GATTEX for children with short bowel syndrome

05/20/2019/by CAPTIS

Ligand licenses VER250840 to Cumulus Oncology

05/20/2019/by CAPTIS

AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility

05/17/2019/by CAPTIS

Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK

05/17/2019/by CAPTIS

ESSA Pharma to acquire Realm Therapeutics

05/16/2019/by CAPTIS

Pfizer’s blood clot drug Fragmin gets FDA approval for pediatric patients

05/16/2019/by CAPTIS

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

We Suggest:

Takeda, Frazier Healthcare collaborate to launch Phathom Pharmaceuticals

0 Comments
/
05/16/2019
Takeda has granted a license to Phathom for the development and…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-16 00:31:512019-05-16 00:31:53Takeda, Frazier Healthcare collaborate to launch Phathom Pharmaceuticals

Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes

0 Comments
/
05/16/2019
According to the company, tolimidone significantly reduced HbA1c…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-16 00:01:062019-05-16 00:01:08Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes

FDA approves Roche’s leukemia drug combo Venclexta plus Gazyva

0 Comments
/
05/16/2019
Venclexta/Venclyxto is a first-in-class targeted medicine that…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-16 00:01:012019-05-16 00:01:04FDA approves Roche’s leukemia drug combo Venclexta plus Gazyva

Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

0 Comments
/
05/15/2019
The results were presented by Eric D. Donnenfeld, M.D., last…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-15 03:02:302019-05-15 03:02:31Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

New biotechnology holding company ElevateBio launches in Cambridge, US

0 Comments
/
05/15/2019
ElevateBio is backed by $150m funding raised through a Series…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-15 02:31:182019-05-15 02:31:20New biotechnology holding company ElevateBio launches in Cambridge, US

Zymeworks enters its first ZymeLink antibody-drug conjugate platform licensing agreement with Iconic Therapeutics

0 Comments
/
05/15/2019
This is the first collaboration leveraging the ZymeLink platform…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-15 01:31:172019-05-15 01:31:19Zymeworks enters its first ZymeLink antibody-drug conjugate platform licensing agreement with Iconic Therapeutics

Pfizer, Merck get FDA nod for Bavencio plus Inlyta to treat advanced RCC

0 Comments
/
05/15/2019
The approval was based on data from the phase III Javelin Renal…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-15 00:01:052019-05-15 00:01:06Pfizer, Merck get FDA nod for Bavencio plus Inlyta to treat advanced RCC

Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia

0 Comments
/
05/14/2019
SEP-363856 was discovered by Sunovion in collaboration with PsychoGenics…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-14 02:31:112019-05-14 02:31:15Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia

Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan

0 Comments
/
05/14/2019
With Daiichi Sankyo’s first commercial sale of MINNEBRO,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-14 01:32:052019-05-14 01:32:06Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan

Lilly’s Cyramza becomes first FDA-approved biomarker-driven therapy in patients with hepatocellular carcinoma

0 Comments
/
05/14/2019
Concurrent with this FDA approval – the fifth for CYRAMZA…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-14 01:01:072019-05-14 01:01:08Lilly’s Cyramza becomes first FDA-approved biomarker-driven therapy in patients with hepatocellular carcinoma

Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma

0 Comments
/
05/13/2019
The designation has been granted for Pomalyst to treat patients…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-13 23:31:082019-05-13 23:31:09Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma

Merck announces results from phase 2 trial of V114 in infants

0 Comments
/
05/13/2019
It is the company’s investigational 15-valent pneumococcal…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-13 04:32:212019-05-13 04:32:22Merck announces results from phase 2 trial of V114 in infants

Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

0 Comments
/
05/13/2019
The results demonstrated Gilenya 0.5mg’s superior efficacy…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-13 03:01:112019-05-13 03:01:12Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

Pfizer opens new biologics clinical manufacturing facility in Massachusetts

0 Comments
/
05/13/2019
Pfizer’s Andover site houses commercial manufacturing and…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-13 02:01:232019-05-13 02:01:24Pfizer opens new biologics clinical manufacturing facility in Massachusetts

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

0 Comments
/
05/13/2019
The study has showed a significantly higher proportion of patients…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-13 01:01:292019-05-13 01:01:30Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Spectrum announces asset purchase and license for immuno-oncology platform

0 Comments
/
05/10/2019
The deal includes an exclusive license for the intellectual property…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-10 03:01:272019-05-10 03:01:29Spectrum announces asset purchase and license for immuno-oncology platform

Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy

0 Comments
/
05/10/2019
MGTA-456 is a cell therapy designed to provide a high dose of…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-10 03:01:252019-05-10 03:01:26Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy

BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

0 Comments
/
05/09/2019
The phase 3 CheckMate -498 trial assessing Opdivo plus radiation…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-09 23:31:552019-05-09 23:31:56BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

Pfizer acquires clinical-stage biotech Therachon

0 Comments
/
05/09/2019
Under the terms of the agreement, Pfizer will acquire Therachon…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-09 04:01:292019-05-09 04:01:30Pfizer acquires clinical-stage biotech Therachon

Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

0 Comments
/
05/09/2019
Through the early-stage trial called DUET-3, Xencor will assess…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-09 03:01:102019-05-09 03:01:11Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

News from Twitter

Twitter
Quantum Genomics
Quantum Genomics
@QuantumGenomics

Nous profitons de la #JournéeMondialeContreLHypertension pour vous rappeler que notre mission est de développer de nouvelles thérapies innovantes pour les besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires. #Hypertension #Firibastat #QuantumGenomics pic.twitter.com/bELl…

reply retweet favorite
12:12 pm · 05/18/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Let's meet at #AAOS2019 in Las Vegas. Feel free to make contact. pic.twitter.com/Cybu…

reply retweet favorite
4:11 pm · 03/14/2019
Twitter
Dr. Alfredo Figueiredo
Dr. Alfredo Figueiredo
@AlfredoFig1

#LowBackPain - a good summary by the European Spine Society @EUROSPINESoc eurospinepatientline… #Orthopaedics #SpineSurgery pic.twitter.com/yo6E…

reply retweet favorite
5:05 am · 02/21/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Happy President's Day from CAPTIS!

reply retweet favorite
5:06 pm · 02/18/2019
Twitter
Medtronic Spine
Medtronic Spine
@Medtronic_Spine

We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…

reply retweet favorite
5:27 pm · 02/01/2019 ·
Retweeted by CAPTIS
Twitter
Arab Health
Arab Health
@Arab_Health

The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Q pic.twitter.com/oasI…

reply retweet favorite
5:35 pm · 01/29/2019 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine #ESMO18 pic.twitter.com/41QL…

reply retweet favorite
6:56 pm · 10/24/2018 ·
Retweeted by CAPTIS
Twitter
Epic CV
Epic CV
@Epic_CV

Read carefully employer's directions on how to apply. #resume #resumetips

reply retweet favorite
7:47 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
World Spine Care
World Spine Care
@WorldSpineCare

Here are 5 Tips to Avoid Back Pain from #WorldSpineDay. #Exercise #Posture #Stress #HealthyEating #Strength pic.twitter.com/AT1D…

reply retweet favorite
7:46 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Neurochecklists
Neurochecklists
@neurochecklists

Large-vessel giant cell arteritis: diagnosis, monitoring and management | Rheumatology | Oxford Academic academic.oup.com/rhe…

reply retweet favorite
7:40 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Stryker Endoscopy
Stryker Endoscopy
@StrykerEndo

Scientists have made an unexpected discovery while investigating the triggering factors of #ColonCancer: Cell stress in combination with an altered microbiota in the colon drives tumor growth. Learn more: ow.ly/JxtK30meLTY pic.twitter.com/U51Q…

reply retweet favorite
7:39 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Implantech
Implantech
@Implantech

If you are in Dallas attending the AAFPRS 12th International Symposium of Facial Plastic Surgery don’t miss out on this Breakfast Symposium tomorrow morning with Dr. William Binder that is sponsored by Implantech! #implantech #superiorpatientaesthetics #implantechrewards #aafprs pic.twitter.com/HCzK…

reply retweet favorite
7:38 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
American College of Cardiology
American College of Cardiology
@ACCinTouch

Less than one month left to submit your science for #ACC19! Abstract & case submissions are due Oct. 16. Learn more: ow.ly/4nyf30lYZxh pic.twitter.com/Mnwv…

reply retweet favorite
4:46 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStory pic.twitter.com/Xuoh…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Integra LifeSciences
Integra LifeSciences
@integra_life

Make plans to visit the Integra LifeSciences Booth# 919 during Plastic Surgery The Meeting September 28th - October 1st. #Integra_LifeSciences #DurableIsBeautiful #PSTM18 #ASPS #PlasticSurgery pic.twitter.com/8QGv…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Fundamental Surgery
Fundamental Surgery
@FundamentalSurg

We are live at #NASS2018 stand 2649. Get hands-on with the world's leading surgical #simulator in #VR with #haptics and experience the future of surgical training. #wearefundamental fundamentalsurgery.c… pic.twitter.com/NgzA…

reply retweet favorite
4:41 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
TRX Orthopedics
TRX Orthopedics
@TRXOrtho

Great things happening at Tissue Regenix! Plan to visit our booth at the AAOS meeting in New Orleans, under the CellRight Technologies banner #5413. @AAOS1

reply retweet favorite
8:34 pm · 03/02/2018 ·
Retweeted by CAPTIS
Twitter
Corin Group
Corin Group
@corintechnology

All evaluation cases for the new Corin Dual Mobility option for the Trinity Acetabular cup system have now been completed and we're looking forward to the full launch. Click lnkd.in/g8ariEY for details #orthopaedics #technology #totalhip #uniquehip pic.twitter.com/SPsy…

reply retweet favorite
8:33 pm · 03/02/2018 ·
Retweeted by CAPTIS
Twitter
Omar Ishrak
Omar Ishrak
@MedtronicCEO

Thank you to our @Medtronic employees around the globe! Q3 saw strong, balanced results, with diversified performance in all groups and regions. #MDTEarnings

reply retweet favorite
8:33 pm · 03/02/2018 ·
Retweeted by CAPTIS
Twitter
Cardiovascular News
Cardiovascular News
@Cardiovasc_bio

#cardiovascular news CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC - CorFlow Therapeutics AG corflowtherapeutics.… today announced that the company will present fundamental new insights into the coronary microci... ow.ly/OlaG50gAElO

reply retweet favorite
8:32 pm · 03/02/2018 ·
Retweeted by CAPTIS
Follow @CaptisCorp

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - copyright@captis.com
  • Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
X
Thank you for visiting our new website! Help us improve, let us know your feedback (Anonymous 2 min survey)
Survey
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top